Clinical Trial Update: Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of low-dose interleukin-2 for birch pollen allergy has completed, with results summarized in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Birch Pollen-induced Allergic Rhinoconjunctivitis

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Allergic Rhinoconjunctivitis to Birch Pollen, With a Positive Skin Prick Test to Birch Pollen | Phase 2 | Status: COMPLETED